Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 PEG Ratio is 0.48 as of Aug. 27, 2026, which is 25% below its 10-year median of 0.64. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 344 Drug Manufacturers companies, Essex Bio-Technology ranks better than 88.66% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Essex Bio-Technology's PEG Ratio or its related term are showing as below:
HKSE:01061'
s PEG Ratio Range Over the Past 10 Years
Min: 0.29 Med: 0.64 Max: 2.28
Current: 0.48
During the past 13 years, Essex Bio-Technology's highest PEG Ratio was 2.28. The lowest was 0.29. And the median was 0.64.
HKSE:01061's PEG Ratio is ranked better than 88.66% of 344
companies
in the Drug Manufacturers industry
Industry Median: 1.76
vs HKSE:01061: 0.48
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Essex Bio-Technology (HKSE:01061) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Essex Bio-Technology PEG Ratio Related Terms
Essex Bio-Technology PEG Ratio Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Essex Bio-Technology (HKSE:01061) has a PEG Ratio of 0.48 as of Aug. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Essex Bio-Technology and its competitors. This is 25% below median its historical median of 0.64. Over the past decade, Essex Bio-Technology's PEG Ratio has ranged from 0.29 to 2.28. According to the industry distribution chart, Essex Bio-Technology ranks #39 out of 344 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Essex Bio-Technology's PEG Ratio too high?
Essex Bio-Technology's current PEG Ratio of 0.48 is 25% below median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 2.28. The Drug Manufacturers industry median PEG Ratio is 1.76. Essex Bio-Technology's value of 0.48 is 72.7% below this industry median. Based on the distribution chart, Essex Bio-Technology ranks #39 out of 344 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #39 out of 344 companies for PEG Ratio. This places Essex Bio-Technology in the top 11% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.76. Essex Bio-Technology's value of 0.48 is 72.7% below this benchmark. Historically, Essex Bio-Technology's own PEG Ratio has ranged from 0.29 to 2.28 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 1.76, Essex Bio-Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.76, based on 344 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current PEG Ratio of 0.48 is 72.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current PEG Ratio is 0.48, which is 25% below median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current PEG Ratio is 0.48, which is 25% below median its 10-year median of 0.64 and 72.7% below the Drug Manufacturers industry median of 1.76. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current PEG Ratio is 0.48 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
PEG Ratio: 0.48 (25% below median its 10-year median of 0.64)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 72.7% below the Drug Manufacturers median (#39 of 344)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
